Hangzhou, China

Zeao Huang

This inventor holds 1 USPTO granted patent and 6 published patent applications, plus 1 CIPO patent. Top assignee: Hangzhou Tianlong Pharmaceutical Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zeao Huang. Retrieved from https://idiyas.com/inventor/zeao-huang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zeao Huang and RNAi Innovation for Hepatitis B

Introduction

Zeao Huang is an inventor based in Hangzhou, China, whose patent work focuses on RNA interference (RNAi) approaches to regulating hepatitis B virus (HBV) gene expression. His disclosed invention describes a double-stranded RNAi agent designed to reduce the expression of one or more HBV genes and disrupt the viral life cycle.

Latest Patents

Huang is associated with 1 patent: “Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof.” The invention comprises an antisense strand and a complementary sense strand that form a duplex region. The antisense strand uses a sequence identified as SEQ ID NO: 8, 11, or 13, or a modified version of one of those sequences.

According to the patent description, cell and animal experiments showed that the RNAi agent can significantly reduce the expression of one or more HBV genes and block the viral life cycle. The disclosed approach may support the development of medicines for diseases related to HBV gene expression.

Career Highlights

Huang is associated with Hangzhou Tianlong Pharmaceutical Co., Ltd. His patent work reflects research into RNA-based strategies with potential applications in treating HBV-related diseases.

Collaborations

The patent lists Gengshen Song and Shuo Yang among Huang’s coworkers, indicating collaboration in the development of the disclosed RNAi technology.

Conclusion

Zeao Huang’s patent describes a targeted RNAi approach intended to suppress HBV gene expression and interrupt viral activity, highlighting the potential of this invention for future therapeutic development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…